With the quickly emerging medications in the Canadian HIV landscape, it is imperative for specialists and primary care physicians to continuously evaluate safety of therapies and HIV regimens, depending on each patient’s history and circumstance.
This program takes you through case studies.
The Learning Objectives are:
- Understand the safety profile of selected NRTI (TAF, TDF, ABC) and the impact of boosted vs. unboosted regimens on this profile.
- Critically evaluate the optimal NRTI regimens for specific patients and clinical contexts.
- Address the impact of genetic mutations and comorbidities on treatment decisions.
November 29, 2022 recording:
Dr. Brian Conway Presenting: CLICK HERE
This education event was an accredited group learning activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Merck and was planned to achieve scientific integrity, objectivity, and balance.
Should you have any questions or need more information about the program please contact Leah Menard at firstname.lastname@example.org.